Sign in to view content

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD

David A. Eichenbaum, MD, FASRS

Video
Published 2019

Related

Wet AMD 2 Symposium
Annual Meeting Talks
2020
One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Episode 12: RPE Stem Cells for Dry AMD with Dr. Mark Humayun
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more